Download - b site at
![Page 1: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/1.jpg)
Clinical Trials: Building Partnerships to Improve Cancer Outcomes
Michigan Cancer Consortium Update
April 21, 2004
![Page 2: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/2.jpg)
The major advancements in cancer prevention and clinical treatment are the
result of clinical research.
![Page 3: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/3.jpg)
Cancer Clinical Trials
• Advance scientific knowledge
• Avoid useless treatment
• Offer options to those who have not responded to standard treatment regimens
• Reporting and analysis of adverse events improve care
![Page 4: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/4.jpg)
ASCO’s Definition of Clinical Trials
• “Clinical investigation in oncology is hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy or epidemiology of neoplastic disease.”
![Page 5: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/5.jpg)
Types of Clinical Trials
• Prevention = test new approaches (meds, vitamins, etc.) that may risk of cancer
EX = Tamoxifen study, STAR Trial• Screening = test best ways to detect cancer in early stages• Treatment = test new treatments (drugs, surgery, radiation,
combinations, or new methods such as gene therapy examples = ---BMT and high dose chemo ---Sentinel node biopsy in breast cancer ---PET replace CT and MRI in staging esophageal and non-small cell lung ca • QOL = also called supportive care trials; explore ways to improve
comfort and quality of life for cancer patients
![Page 6: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/6.jpg)
Defining Clinical Trials Phases
Phase I = HOW DOES TREATMENT AFFECT HUMANS?
TEST:• safety• toxicity• feasibility
Small number of patients (15- 30) with advanced cancer who have exhausted other treatments; less likely they will personally benefit
![Page 7: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/7.jpg)
Defining Clinical Trials Phases
Phase II = DOES THE DRUG DO WHAT IT’S SUPPOSED TO DO?
• Test effect on a single type of cancer
Slightly larger # patients (30 - 50) than Phase I trialPatients for whom conventional treatment has failed; some possibility
that patient will benefit from the treatment.
Only ~ 33% of drugs tested in Phase II are found safe, effective enough to go to Phase III
![Page 8: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/8.jpg)
Defining Clinical Trials Phases
Phase III = IS THE NEW DRUG A BETTER ALTERNATIVE TO CURRENT PRACTICE?
• Last step in testing• Randomized controlled trials that determine how a
new treatment compares with the current, standard treatment (Participants are randomized into 2 groups:standard of care vs. new treatment
Require large #’s patients (100’s or 1000’s)-- conducted thru many settings nationwide
![Page 9: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/9.jpg)
1997
• Increase participation in cancer clinical trials selected as a priority of the MCC
![Page 10: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/10.jpg)
U of M and MSHO Convene the Clinical Trials Action Plan Committee
• Karmanos Cancer Institute• Henry Ford Health System• Michigan State University
Cancer Center• Ann Arbor CCOP• Grand Rapids CCOP• Kalamazoo CCOP• Blue Cross Blue Shield
• Coalition of National Cancer Cooperative Groups
• Michigan Osteopathic Association
• Oncology Nursing Society• American Cancer Society• Cancer Information
Service• Amgen
![Page 11: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/11.jpg)
1998-1999 The Goal, Action Plan, Timelines and Implementation Strategies
are Identified
“By the year 2005, double the enrollment and increase diversity in
cancer clinical trials”
![Page 12: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/12.jpg)
Implementation Plan
• Establish a mechanism to measure clinical trials participation
• Reduce physician and/or provider bias
• Resolve insurance coverage issues
• Collaborate with minority agencies to increase diversity
• Influence patient attitudes• Advocate for
improvement in clinical trial design and eligibility
• Expand access and infrastructure support to community physicians
• Support efforts by accrediting bodies to include clinical trial participation criteria
![Page 13: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/13.jpg)
Establishing a Mechanism to Measure Michigan Patients and Providers Participation in Clinical Trials
![Page 14: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/14.jpg)
Clinical Trials Enrollment Pilot
– Collaboration among Michigan Public Health Institute, MCC Clinical Trials Action Plan Committee, MSHO, MDCH and Michigan Working Group to Improve Cancer Outcomes members.
Current Project Leader: Sandra Herman, Ph.D
![Page 15: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/15.jpg)
Cancer Clinical Trials Enrollment Pilot Study
• Develop a baseline on cancer clinical trials enrollments
• Develop methodology to– Identify trial sites– Collect enrollment data
• Test feasibility of methods & materials
![Page 16: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/16.jpg)
Need for a pilot study
• Baseline data are critical
• No single source of enrollment data
• Goal to increase enrollments in clinical trials
![Page 17: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/17.jpg)
Who participated?
• Target population– Universities– Hospitals– Cancer centers– Community Clinical Oncology Programs
(CCOPs)
• 53 eligible institutions identified
![Page 18: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/18.jpg)
Pilot Study Results
Figure 1. Gender of Persons Enrolled
Unknown13%
Male37%
Female50%
Figure 2. Ethnicity of Persons Enrolled
83.1%
14.6%2.4%
0.0%10.0%20.0%30.0%40.0%50.0%60.0%70.0%80.0%90.0%
100.0%
White Black All other
Figure 3. Ages of Persons Enrolled
2.8%
24.0%
51.4%
16.6%
0.0%10.0%20.0%30.0%40.0%50.0%60.0%70.0%80.0%90.0%
100.0%
15-29 30-49 50-69 70 +
Figure 4. Erollment by Sponsor Type
NIH55%Intramural
26%
Industry19%
![Page 19: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/19.jpg)
Moving Forward – Funding the Next Phase
![Page 20: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/20.jpg)
2004 Study Plans
• Target population– Major cancer centers– Community Clinical Oncology Programs– Universities/individual physicians with industry
sponsored trials– Universities/individual physicians with
institutional sponsored trials
![Page 21: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/21.jpg)
2004 Study Plans
• Establish routine protocol to collect enrollment data
• Measure change over 3 years in– Number of patients enrolled– Diversity of patients enrolled
• Monitoring tool for MCC objective on clinical trials
![Page 22: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/22.jpg)
Data Sources
• CDUS/CTES data– Studies reporting data as part of Cancer
Therapy Evaluation Program– No additional reporting on these trials
![Page 23: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/23.jpg)
Data Sources
• Industry– Pharmaceutical & bio-tech companies– Funded by For-profit unless investigator
initiated
• Institutional– Investigator initiated non-industry trials– Investigator initiated industry trials– R01 trials
![Page 24: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/24.jpg)
Data Elements
• Number accrued by type of trial &– Phase
• Treatment, prevention, cancer control, early detection
– Patient gender– Patient race/ethnicity– Age group
• 18-30, 31-49, 50-69, 70 or older
![Page 25: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/25.jpg)
2004 Time Line
• March – April– Research investigators & managers register
online, by email, or mail– CDUS data requested
• May– Data collection forms mailed
• May – July– Data submitted online, by email, or mail
![Page 26: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/26.jpg)
2004 Time Line
• August– Final follow-up on data submissions– CDUS data received for 2001, 2002, 2003
• September– Preparation of report
![Page 27: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/27.jpg)
Changes in 2004 Study
• Clinical trials utilizing Cancer Therapy Evaluation Program do not need to report
• Online data collection available
![Page 28: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/28.jpg)
Addressing Physician Bias
![Page 29: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/29.jpg)
Physician Biases May Be the MOST Important Influence in Patient
Enrollment
Patients will enroll when the physician believes that the trial is sound medically and scientifically and that as an “expert surrogate” he would be willing to personally participate in the trial
![Page 30: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/30.jpg)
2000 MSHO MI Oncologists’ Clinical Trials Assessment
MSHO & Pharmacia partner to determine Michigan Medical Oncologists:
• Current level of clinical trial participation
• Actual and perceived barriers to clinical trial participation
• Attitudes about clinical research
![Page 31: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/31.jpg)
MSHO Clinical Trials Assessment Sample Questions (Strongly Agree to Strongly Disagree)
1. My practice is limited by the hospital or HMO formulary.
2. Hospital policy dictates some of my treatment options.
3. Protocols do not include all patients and are therefore too restrictive.
4. My income is adversely affected by placing patients on clinical trials.
5. Protocols do not always include what I consider standard therapy.
6. I am concerned about being audited by insurers who exclude payments for clinical trials.
7. Other responsibilities prevent me from learning what I need to know to place patients on clinical trials.
8. Protocols require a large increase in time spent on each patient.
![Page 32: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/32.jpg)
MSHO Oncologists’ Assessment Results
• Rough measure of current participation levels• Survey results confirmed many perceived
research concerns and barriers • Identified possible behavioral change
opportunities for physicians who do not enroll patients on studies
• Revealed a large information gap – 25% of responding oncologists had very limited clinical trial awareness
![Page 33: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/33.jpg)
Physician Communication and Patient Decisionmaking about Cancer Clinical Trials
Terrance L. Albrecht, Ph.D.
John C. Ruckdeschel, M.D.
Louis A. Penner, Ph.D.
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Presented to Grand Rounds, MD Anderson Cancer Center, Houston, TX,
November 17, 2003.
Not for citation without permission.
![Page 34: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/34.jpg)
Reasons Patients Do or Do Not Enroll in Cancer Clinical Trials
DO ENROLL: DO NOT ENROLL:• Perceive their needs not
physician’s priority• Disrupt quality of life, functional
abilities• Anxiety about randomization • Worry might not receive best
treatment• Concern about logistical difficulties• Perceive insurance problems • Concern about excessive toxicity• Poor understanding of study• Family against study participation• Worry about excessive burden on
family/friends
Trust in their physician
Physician recommended study
Physician responsive to questions and issues
Encouragement by family
Manageable side effects
Altruism
Desire to live
Albrecht,T. Ruckdeschel et al 2003
![Page 35: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/35.jpg)
– Accrual more likely when MD:• reviewed items in informed consent document, was
supportive, responsive and reflective
• discussed benefits, side effects, patient concerns and resources to manage concerns
Physicians using both legal/info and social influence strategies enrolled
more patients
Albrecht, T, Ruckdeschel et al 2003
![Page 36: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/36.jpg)
Primary Care Providers Attitudes About Cancer Treatment Clinical Trials
Presenters/Authors:
Barbara Given, Charles W. Given,
Aaron Scholnik, Pam Patterson and Paula Sherwood
Michigan State University
East Lansing, MI
02-606
![Page 37: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/37.jpg)
Providers Need to:
• Provide patient information about trials and their value to patients.
• Provide information to reduce uncertainty.• Watch interaction – demeanor of physician critical
to patient decision.• Providers need to decrease logistic barriers to trial
participation.• Encourage and communicate with patients to
facilitate understanding.
02-624
![Page 38: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/38.jpg)
Recommendations
• Policies and funding should be aimed toward creating and implementing educational sessions on clinical trials for both physicians and NPs.
• Education should be included in NP programs as well as medical school and residency programs to establish basic patterns of referral.
• This education should be continued with a variety of techniques and mechanisms.
• Efforts need to be directed toward making information appropriate to primary care practice.
02-622
![Page 39: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/39.jpg)
Educational efforts targeted• To physicians and NPs that practice in rural settings.• To physicians that practice in an urban setting and NPs
that practice in a suburban setting.• To younger physicians.• To NPs in general.• Focus on:
– General knowledge as well as how to access trials.– Potential barriers to patient access.– Responsibilities when a patient enters a trial.
• Information on the scientific design and oversight and primary care of patients on trials.
02-623
![Page 40: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/40.jpg)
![Page 41: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/41.jpg)
Categories of Approval
Network Cancer Program (NCP)
NCI-designated program (NCIP) Comprehensive Cancer Program
Teaching Hospital Cancer Program (THCP)
Community Hospital Comprehensive Cancer Program (COMP)
Community Hospital Cancer Program (CHCP)
Hospital Associate Cancer Program (HACP)
Affiliate Hospital Cancer Program (ACP)
Integrated Cancer Program (ICP)
Freestanding Cancer Center Program (FCCP
![Page 42: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/42.jpg)
American College of Surgeons: Commission on
Cancer Research Program Standards
• Information about the availability of cancer-related clinical trials is provided to patients through a formal mechanism
• As appropriate to the category, the required percentage of cases is accrued to cancer-related clinical trials on an annual basis
• The commendation percentage of cases for the category is accrued to cancer-related clinical trials each year
![Page 43: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/43.jpg)
Influencing Patient and Family Attitudes
![Page 44: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/44.jpg)
44
Characteristics of Patients Who Enter Clinical Trials
Principal Investigators:Aaron Scholnik, M.D.Charles Given, Ph.D.
Barbara Given, Ph.D., R.N., F.A.A.N.
Project Manager:Pam Patterson, M.S., R.N.
Data Manager/Analyst (MSU-DCC):Jian-Ping He, M.D., M.S.
![Page 45: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/45.jpg)
Conclusions
To improve accrual to cancer trials we should 1. Enhance the recognition, visibility, and credibility of
those physicians & institutions that participate in cancer clinical trials
2. Educate the public about the benefits of participating in clinical trials
3. Educate our medical colleagues about the benefits of referring their patients to physicians & institutions that participate in cancer clinical trials
![Page 46: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/46.jpg)
Conclusions
4. Develop more trials – adjuvant & non-adjuvant that serve males and disease sites other than breast
5. Offer all trials to appropriate, good performance status elderly patients
6. Work with our ethicists, IRB’s, and behavioral experts to structure our presentation of clinical trials, including “consent forms” to take advantage of the importance of “doctor influence” and “altruism” and to better present the scope of “positive” and “negative” effects of investigational treatments
![Page 47: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/47.jpg)
Industry Generated Patient Education
![Page 48: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/48.jpg)
Insurance Industry Publications
![Page 49: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/49.jpg)
Cancer Information Service Clinical Trials Train the Trainer
Program
![Page 50: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/50.jpg)
Using Media
• Publication inserts• Editorial Boards• Key local contacts for
press, radio and TV• Advertising
![Page 51: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/51.jpg)
Resolving Insurance Coverage Issues for Those Enrolled in Clinical
Trials
![Page 52: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/52.jpg)
The Issue
• The expansion of quality clinical research needed to improve cancer outcomes is impeded by patients’ and providers’ reluctance to participate in trials without assurance of health plan coverage.
![Page 53: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/53.jpg)
The Dialogue Begins
March 5, 1999
Cancer Clinical Trials: Building Partnerships for the Future
![Page 54: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/54.jpg)
November 3, 1999Senator Schwarz Convenes Meeting
at the Capitol
• A voluntary agreement for routine patient care cost coverage among those most involved in the process was encouraged by the MDCH.
![Page 55: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/55.jpg)
“Cooperation not legislation offers the greatest advantage to
Michigan’s cancer patients.”
The Honorable John J. H. Schwarz, M.D.
![Page 56: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/56.jpg)
Michigan Working Group to Improve Cancer Outcomes
The Economic Alliance for Michigan
Prostate Education & Support Network
![Page 57: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/57.jpg)
What Did Payers Say About Clinical Trial Coverage Prior to 2000?
“Manage the benefit!”
• View all trials as “investigational”• Build the infrastructure for denial
Carver – Michigan Working Group Meeting February 23, 2000
![Page 58: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/58.jpg)
Reality for Payers
• We already pay excessively for care in this population
• Return on investment is poor
• The cost of clinical trial participation is at worst comparable to usual care
Carver – Michigan Working Group Meeting February 23, 2000
![Page 59: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/59.jpg)
• Educated medical directors
• Enlightened administrators
• Educated patients• Educated physicians
Solution=Barrier Removal
Carver – Michigan Working Group Meeting February 23, 2000
![Page 60: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/60.jpg)
Consensus Guidelines for Coverage of Routine Patient Care Costs for Those
Enrolled in Clinical Trials
![Page 61: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/61.jpg)
Michigan Working Group to Improve Cancer Outcomes
Executive GroupPhilip Stella, MD
Mary Malloy
Tom Simmer, MD Sam Silver, MD Marshall Katz, MD
Gene Farnum
Carolyn Schmit, RN
Bob Chapman, MD
Mike Rosenberg, MD Carol Callaghan
Sue Haviland
Aaron Scholnick MD Noah Smith Chris Goeschels RN
Beverly Blaney, MD Ellen Sprental-Nakervis
Charles Schiffer, MD Chuck Gayney
Laura Champagne
Joe Carver, MD
Bruce Carl, MD MBA Jim Ball Sheldon Schwartz Ed Ervin Oliver Kim
Prostate Education& Support Network
The Economic Alliance for Michigan
![Page 62: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/62.jpg)
Clinical Trials Costs/Responsibilities Model
• Administrative Costs (TrialSponsor)
• Investigative Agents (Pharmaceutical Company)
• Routine Patient Care Costs (Insurer/Accounts)
• Exceptional Tests (Trial Sponsor)
![Page 63: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/63.jpg)
Payer Issues and Restraints
• Contract language
• Extrapolation
• Fiduciary responsibility
• Moral responsibility
• Cost
![Page 64: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/64.jpg)
Insurers’ Perspective
Traditional Experience
• Insurer paid for routine care because system could not identify services performed in a clinical trial from other services.
• Payments denied based on claims edits are often successfully appealed.
• Denials for investigational services lead to lawsuits
Simmer – 2001 MCC Annual Meeting
![Page 65: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/65.jpg)
Insurers’ Perspective
Traditional Experience
• Policies discourage participation in clinical trials.• Off protocol delivery of unproven services
discourages participation in clinical trials.• Unproven services become standard practice
without adequate scientific validation.• Medical care less evidence based than optimal
Simmer – 2001 MCC Annual Meeting
![Page 66: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/66.jpg)
Outline of the Consensus Document
• Clinical Trial Definitions and Exclusions
• Rationale for Supporting Clinical Research Efforts
• Criteria for “Approved” Clinical Trials
• Costs Associated with Cancer Clinical Trials
• Policy Issues and Concerns
• Essential Elements of Consensus Guidelines
![Page 67: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/67.jpg)
Key Elements of the Consensus Guidelines
• Voluntary agreement• Rigorous patient
protection safeguards are addressed
• Peer review scrutiny of trial design for therapeutic benefit & scientific validity is required
• Coverage applies to Phase II and Phase III
• Off Protocol use of any protocol is not covered under this agreement
• Coverage includes costs associated with routine patient care, delivery of the investigational agent or service and adverse effects
![Page 68: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/68.jpg)
Health Plan Discretion
• Health Plans may grant “deemed status” to investigators of institutions committed to principles represented in this document.
• Health Plans may revoke “deemed status” for violations or abuse of principles represented in this document.
• Clinical trials related to cancer prevention and/or performed at institutions not listed in document criteria may be covered outside the scope of this agreement by individual health plans according to their policies and procedures.
![Page 69: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/69.jpg)
Insurers’ Perspective
Implementing the Guidelines
• Insurers cover routine costs of medical services delivered in clinical trials.
• Insurers override payment edits for off-label and unproven indications when members are enrolled in clinical trials.
• Off protocol delivery of investigational treatment remains beyond scope of coverage
Simmer – 2001 MCC Annual Meeting
![Page 70: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/70.jpg)
Insurers’ Perspective Benefits
• Improved participation in clinical trials
• Better scientific validation of medical care
• Improved cooperation between investigators and insurers
• More effective restriction of investigational services to investigational settings
Simmer – 2001 MCC Annual Meeting
![Page 71: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/71.jpg)
Insurers’ PerspectiveBenefits
• Direct Costs– Coverage for a better standard of care than is currently
being reimbursed
• Indirect Costs– Better outcomes for cancer patients– Fewer costly reviews– Reduced litigation– Improved public relations for insurers and their accounts– Advancement of the science
Simmer – 2001 MCC Annual Meeting
![Page 72: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/72.jpg)
MAHP Clinical Trials Resource Packet to
Primary Care Physicians
![Page 73: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/73.jpg)
Collaboration with Minority Agencies to Increase Diversity
![Page 74: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/74.jpg)
Exploratory Meeting/ African American Thought Leaders
• MDCH identifies and invites prominent African American leaders to meet with the directors of Michigan’s research programs.
• Feasibility of a “Blue Ribbon” advisory panel will be proposed
for collaboration on strategies to resolve insufficient minority participation in clinical research.
• Group initially convened by MDCH, December, 2000
![Page 75: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/75.jpg)
Improving Cancer Outcomes of African Americans In Michigan
Presented by: E. Yvonne LewisMichigan Cancer Consortium Board Meeting
April 21, 2003Lyon Meadows Conference Center
New Hudson, MI
![Page 76: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/76.jpg)
Project Overview
• February 15, 2002
– Minority Enrollment Work Group of the Michigan Cancer Consortium provided an overview of the concept for a project to “Increase African American Participation in Cancer Clinical Trials”
– Concept was intended to have statewide impact, involving five large communities
– A total of 1,147,375 African Americans resided in these counties, constituting 81.3% of Michigan’s black population
![Page 77: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/77.jpg)
Identified Communities• Detroit (Wayne County)
• Flint (Genesee County)
• Lansing (Ingham County)
• Saginaw (Saginaw County)
• Pontiac (Oakland County)
![Page 78: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/78.jpg)
Problem Statement
African Americans are 33% more likely to die of cancer than European Americans and are two times more likely to die of cancer than Asians, Native Americans, and Hispanics.
The purpose of this initiative is to reduce the unequal burden of cancer and improve the quality of life of African Americans in Michigan.
![Page 79: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/79.jpg)
Community Perspective
• Engage African American community representatives from across socio-economic strata to discuss and plan ideas to best engage members of their communities to address the issues of cancer
• Form teams in each community to ensure the goals of the project are met
![Page 80: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/80.jpg)
Community Project Design
• 2-3 representatives from each community were identified to review the initial concept
• Additional representatives were engaged to develop the Design Team
• Each team would develop strategies to engage the larger community
• All teams would meet to develop a statewide strategy
![Page 81: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/81.jpg)
Project Goals
• Increase awareness about cancer in the African American Community
• Increase knowledge about cancer
• Increase communication about cancer
• Decrease myths about cancer
• Increase screening and utilization of cancer screening programs
![Page 82: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/82.jpg)
Data Collection
• Modified Behavioral Risk Factor Survey (BRFS)
• Specifically surveyed African Americans in 5 communities
• 2194 respondents – overall response rate 52.7%
![Page 83: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/83.jpg)
Preliminary Outcomes
• Sample Statements– “Surgery can cause cancer to spread to other parts of
the body”– Range 62.3 – 79.9
– Some cancers can be prevented– Range 84.4 – 93.8
– A diagnosis of cancer is a death sentence– Range 4.8 – 33.5
– A Higher Power decides if a person survives or dies from any cancer
– Range 67.9 -82.9
![Page 84: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/84.jpg)
Preliminary Outcomes
• African Americans are 2 times as likely to have a fear of finding cancer
• 14% suspected that there is no cure
• African Americans are more fatalistic
![Page 85: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/85.jpg)
Preliminary Outcomes
• Margin of 2:1 – African Americans found it more difficult to
communicate about cancer
– Believe that early diagnosis means more time to worry
– More likely to have difficulty arranging transportation and childcare
![Page 86: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/86.jpg)
Work Plans
• Each community was asked to develop a work plan and strategies
• Each community would develop at least two interventions– 1) Focused – addressing a specific segment of
the African American community– 2) Community wide – addressing the broader
community to promote awareness and involvement
![Page 87: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/87.jpg)
Detroit Design Team• Focused Intervention – Parish Nurse Community Cancer Education Outreach
• April 21, 2004
Training session to support Parish Nurses in collectively addressing
cancer in the African American community.
• Community Wide Intervention– City Council Town Hall Meeting
• Mid May 2004
Panel Discussion on cancer in the African American community
– Praise Fest: Cancer Education & Screening
• June 13 & 14, 2004
Host an interactive health segment at this event that would include celebration of life, honoring survivorship; information workshops,
BCCCP recruitment, screening, and risk assessments.
![Page 88: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/88.jpg)
Flint Design Team• Focused Intervention
– Faith Based Leadership Series• May 20 & 21, 2004
A training session to support faith community leaders in collectively addressing cancer in the African American
community.
• Community Wide Intervention – Family Reunion BBQ
• August 21, 2004
Citywide event to mobilize the African American community and engage them around the issue of cancer.
![Page 89: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/89.jpg)
Lansing Design Team• Focused Intervention
– Lift Every Voice: Colorectal Cancer Intervention
• March 18, 2004 Training • April –May, 2004 Implementation
Modifications of the Tell-A-Friend Model to address colorectal cancer
in the African American community.
• Community Wide Intervention– Straight Talk About Cancer
• September 2004• In partnership with the American Cancer Society host a training
session to support African American community leaders in collectively addressing cancer in the African American community
and spreading the message to their constituencies
![Page 90: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/90.jpg)
Saginaw Design Team• Focused Intervention
– County Wide Essay Contest
• April 19-29, 2004
Engage school age children and their families through an essay contest. Six schools identified - Houghton, Jones, Heavenrich, & Claytor Elementary Schools and Central, Webber, & Ricker Middles Schools
• Community Wide Intervention– Health Expo
• June 5-6, 2004
Engage the larger community by partnering with Greater Coleman Temple C.O.G.I.C. in African American Health Expo. ICOAA will host workshops and panel discussions that address cancer in the
African American community.
![Page 91: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/91.jpg)
MarchApril May June July August September
SaginawMarchSchool
Principal’s Orientation
LansingMarch 18, 2004Lift Every Voice
Training
FlintMarch 31, 2004Family Reunion Implementation
Team Orientation
DetroitMid-May
City Council Town Hall Meeting
FlintMay 20& 21,
2004Faith Leaders
Training
SaginawJune 5, 2004
African American Health Expo
DetroitJune 12 & 13, 2004
Praise Fest
FlintAugust 21, 2004Family Reunion
LansingEarly- Sept.Straight Talk About Cancer
SaginawEssay Contest
LansingLift Every Voice Implementation
DetroitApril 21, 2004Parish Nurse
Training
Timeline
![Page 92: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/92.jpg)
Project Staff
• Project Director• E. Yvonne Lewis, Executive Director
Faith Access to Community Economic Development
• Project Specialist• Latecia Matthews
• Community Design Team
• Community Liaisons
![Page 93: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/93.jpg)
Acknowledgements• Project Support
• A special thank you to the Steering Committee of the Cancer Clinical Trails Committee and the Minority Enrollment Work group of the Michigan Cancer Consortium as well as:
– MDCH Cancer Section for funding the project• Carol Callaghan – Director of Chronic Disease – MDCH
• Dr. Phil Stella• Patricia Brookover – Michigan Department of Community Health
• Sue Brown - Michigan Department of Community Health
![Page 94: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/94.jpg)
Expanding Access and Infrastructure Support to Community Physicians
![Page 95: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/95.jpg)
Growth of CCOPs in Michigan
Kalamazoo CCOP
Beaumont CCOP
![Page 96: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/96.jpg)
Creating Awareness of Advances in Clinical Trial Design & Research
Resources
![Page 97: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/97.jpg)
![Page 98: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/98.jpg)
• ABOUT THE CTSU The Cancer Trials Support Unit (CTSU) is a pilot project sponsored by the National Cancer Institute (NCI) for the support of a national network of physicians to participate in NCI-sponsored Phase III cancer treatment trials. The majority of these trials are sponsored by the adult Cooperative Clinical Trials Groups listed here.
ACOSOG - (American College of Surgeons Oncology Group)
CALGB - (Cancer and Leukemia Group B)
ECOG - (Eastern Cooperative Oncology Group)
GOG - (Gynecologic Oncology Group)
NCIC CTG - (National Cancer Institute of Canada Clinical Trials Group)
NCCTG - (North Central Cancer Treatment Group)
NSABP - (National Surgical Adjuvant Breast and Bowel Project)
RTOG - (Radiation Therapy Oncology Group)
SWOG - (Southwest Oncology Group)
CTSU Objectives:
• Increase physician and patient access to NCI-sponsored clinical trials • Streamline and standardize trial data collection and reporting • Reduce regulatory/administrative burden on investigators participating in NCI-sponsored Cooperative Group clinical
trials (phases 1-3)
The Cancer Trials Support Unit (CTSU) is a pilot project sponsored by the National Cancer Institute (NCI) for the support of a national network of physicians to participate in NCI-sponsored Phase III cancer treatment trials. The majority of these trials are sponsored by the adult Cooperative Clinical Trials Groups listed here.
ACOSOG - (American College of Surgeons Oncology Group)
CALGB - (Cancer and Leukemia Group B)
ECOG - (Eastern Cooperative Oncology Group)
GOG - (Gynecologic Oncology Group)
NCIC CTG - (National Cancer Institute of Canada Clinical Trials Group)
NCCTG - (North Central Cancer Treatment Group)
NSABP - (National Surgical Adjuvant Breast and Bowel Project)
RTOG - (Radiation Therapy Oncology Group)
SWOG - (Southwest Oncology Group)
CTSU Objectives:
• Increase physician and patient access to NCI-sponsored clinical trials
• Streamline and standardize trial data collection and reporting
• Reduce regulatory/administrative burden on investigators participating in NCI-sponsored Cooperative Group clinical trials (phases 1-3)
PLEASE NOTE: Cooperative Group sites located within
The Cancer Trials Support Unit (CTSU) is a pilot project sponsored by the National Cancer Institute (NCI) for the support of a national network of physicians to participate in NCI-sponsored Phase III cancer treatment trials. The majority of these trials are sponsored by the adult Cooperative Clinical Trials Groups listed here.
ACOSOG - (American College of Surgeons Oncology Group)
CALGB - (Cancer and Leukemia Group B)
ECOG - (Eastern Cooperative Oncology Group)
GOG - (Gynecologic Oncology Group)
NCIC CTG - (National Cancer Institute of Canada Clinical Trials Group)
NCCTG - (North Central Cancer Treatment Group)
NSABP - (National Surgical Adjuvant Breast and Bowel Project)
RTOG - (Radiation Therapy Oncology Group)
SWOG - (Southwest Oncology Group)
CTSU Objectives:
• Increase physician and patient access to NCI-sponsored clinical trials
• Streamline and standardize trial data collection and reporting
• Reduce regulatory/administrative burden on investigators participating in NCI-sponsored Cooperative Group clinical trials (phases 1-3)
PLEASE NOTE: Cooperative Group sites located within
![Page 99: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/99.jpg)
• Assurances and IRB Registration
• Compliance Oversight
• Education
• Policy Guidance
• Quality Program Improvement
• Workshops
![Page 100: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/100.jpg)
Available Trainings for Staff New to Clinical Research
• One day CE workshop
• Collaboration between MSHO and Bristol Myers Squibb Oncology
• No cost to physician offices
![Page 101: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/101.jpg)
Locating Information on Current Trials
![Page 102: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/102.jpg)
• Call your American Cancer Society toll free: 1-800-303-5691 • American Cancer Society/EmergingMed Clinical Trials Matching Service
• This free Clinical Trial Matching and Referral Service is made available to American Cancer Society visitors through a collaboration with EmergingMed. Please note that EmergingMed maintains its own privacy policy and EmergingMed utilizes a separate online account registration to store clinical trial results.
• Fill out one questionnaire and within seconds you'll know if your profile matches
any clinical trials in our system. The EmergingMed database contains more than 3,000 clinical trials for treatment, prevention and early detection of cancer. The order in which match results are displayed does not reflect that any clinical trial is better or more appropriate for you than any other match listed.
• If you want more information about one or more clinical trials, you can ask that an American Cancer Society Cancer Information Specialist contact you by phone or by email. They can also connect you at your request to the doctors and nurses conducting the trials that you have matched. Read more
![Page 103: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/103.jpg)
• Updated: 12/18/2001
Related Pages:Search for Clinical TrialsNCI's PDQ® database of cancer clinical trials.User's Guide for PDQ® Clinical Trials SearchUser's guide for the Physician Data Query (PDQ) clinical trials database, explaining contents, how to use the database (including search techniques), comprehensiveness, and how to utilize results.About the PDQ® Editorial BoardsDescription of the PDQ editorial boards.
![Page 104: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/104.jpg)
• Welcome to TrialCheckSM, Version 1.0• The Coalition of National Cancer Cooperative Groups is proud
to offer TrialCheckSM, a new Web-based application. TrialCheckSM gives doctors, nurses, patient advocates, and other healthcare professionals a "real-time" search tool that quickly queries and screens hundreds of cancer clinical trials.
• TrialCheckSM provides nationwide locations where trials are open and enrolling patients. It's easy, customizable through the coordinator function, and will soon be portable in PDA format. TrialCheckSM helps physicians screen trials for their patients. TrialCheckSM enables advocates to be more effective in providing specific trial information to people who call their organizations.
![Page 105: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/105.jpg)
How Do We Proceed?
![Page 106: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/106.jpg)
MCC Collaboration:Measuring Clinical Trial Enrollment in
Michigan• Champion importance of study with research
investigators and managers – intervening with those who do not respond to the survey
– Health system members
– Michigan Health and Hospital Association
• Continue to Seek Financial Support to Complete Project
– MSHO
![Page 107: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/107.jpg)
MCC Collaboration:Addressing Physician Bias
• Educate our medical colleagues about the benefits of referring their patients to physicians & institutions that participate in cancer clinical trials.– Michigan Association of Health Plans & Individual Payers– Michigan Academy of Family Physicians– Michigan Osteopathic Association– Michigan Primary Care Association– MSHO– Michigan State Medical Society
• Enhance the recognition, visibility, and credibility of those physicians & institutions that participate in cancer clinical trials– MCC Award
![Page 108: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/108.jpg)
MCC Collaboration:Addressing Physician Bias
• Highlight participation in Clinical Trials as a Quality Indicator for Providers and Institutions– Recognition of American College of Surgeons Research
Standards
– Health Plans and Purchasers of Healthcare should be encouraged to use clinical trial participation as a benchmark for program excellence
![Page 109: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/109.jpg)
MCC Collaboration:Influencing Patient and Family
Attitudes• Educate cancer patients and their families about the
benefits of participating in clinical trials • ACS• Health Departments• Michigan Association of Health Plans & Individual Plans• Cancer Information Service – Train the Trainer• ONS• Michigan Academy of Family Physicians• Michigan Dietetics Association• Michigan Primary Care Association
– Work with Patient Advocacy Groups to insure awareness of Michigan Clinical Trial Issues
![Page 110: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/110.jpg)
MCC Collaboration:Influencing Patient and Family
Attitudes• Engage Media/Public Press
– Identify and develop partnering opportunities with pharmaceutical companies using their marketing, education and funding resources.
– Use editorial boards, local contacts in print, radio & TV
• ACS• Healthcare Systems – Public Relations Departments• Health Plans – Marketing Departments
![Page 111: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/111.jpg)
MCC Collaboration:Resolving Insurance Coverage
Issues• Promote awareness of the Guidelines to providers,
payers and purchasers of healthcare.– BCBSM– HAP– MAHP– MSHO– Michigan Working Group to Improve Cancer Outcomes
• Inclusion of Phase I trials, Prevention and Screening Trials in the Guidelines– Michigan Working Group to Improve Cancer Outcomes
![Page 112: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/112.jpg)
MCC Collaboration:Resolving Insurance Coverage
Issues• Long term organization and funding of the Michigan
Working Group to Improve Cancer Outcomes– MSHO– Pharmaceutical Industry Grants– Health Plan/Industry Foundations
• A mechanism to review promising trials that do not fall within the “deemed” status criteria
• Development of a registry of current “deemed” clinical trials in Michigan
![Page 113: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/113.jpg)
MCC Collaboration:Collaborating with Minority
Community Thought Leaders to Increase Clinical Trials of
Underrepresented Populations
• ACCESS
• Faith Access to Community Economic Development
• Healthy Asian Americans project
• Inter-Tribal Council of Michigan
• National Association of Hispanic Nurses
![Page 114: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/114.jpg)
MCC Collaboration:Expanding Access and Infrastructure
Support to Community Physicians
• Contribute to the growth of CCOPs and Networks• Promote Awareness and Access to Resources for
Community Physicians to Participate in Trials• Support Research Managers’ Networking
Opportunities– MSHO
– MDCH
![Page 115: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/115.jpg)
Clinical Trial Action Plan Modifications
• Extend Goal Deadline to 2006
• Modify Workplan
– Dedicated Michigan Clinical Trial Registry may be satisfied with collaboration/modification of ACS and other registries.
– Professional Education efforts to be revisited
![Page 116: b site at](https://reader036.vdocument.in/reader036/viewer/2022081414/54c7742b4a7959f3038b46e1/html5/thumbnails/116.jpg)